List of Excipients in Branded Drug TOVIAZ

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Pfizer Laboratories Div Pfizer Inc	TOVIAZ	fesoterodine fumarate	0069-0242	ALUMINUM OXIDE
Pfizer Laboratories Div Pfizer Inc	TOVIAZ	fesoterodine fumarate	0069-0242	CELLULOSE, MICROCRYSTALLINE
Pfizer Laboratories Div Pfizer Inc	TOVIAZ	fesoterodine fumarate	0069-0242	GLYCERYL DIBEHENATE
Pfizer Laboratories Div Pfizer Inc	TOVIAZ	fesoterodine fumarate	0069-0242	HYPROMELLOSE

TOVIAZ Excipient Strategy and Commercial Opportunities

Last updated: August 12, 2026

TOVIAZ, the brand name for fesoterodine fumarate, is an extended-release oral tablet for overactive bladder. Its commercial formulation uses a conventional hydrophilic matrix and film-coating system rather than a highly differentiated delivery platform. The strongest excipient opportunities are therefore in generic substitution, lower-cost manufacturing, lactose-free reformulation, improved swallowability, dose flexibility, and regional regulatory adaptation.

TOVIAZ was developed by Schwarz Pharma and commercialized by Pfizer. The FDA approved it in 2008 for adults with urge urinary incontinence, urgency, and urinary frequency associated with overactive bladder.[1] The product is marketed in 4 mg and 8 mg extended-release strengths.

What excipients are used in TOVIAZ extended-release tablets?

TOVIAZ uses a matrix tablet with a polymeric release-controlling system and a conventional film coat. The FDA prescribing information identifies the following inactive ingredients:[1]

Formulation component	Reported excipients	Technical function
Core matrix	Lactose monohydrate	Filler and tablet mass
Core matrix	Microcrystalline cellulose	Diluent, binder, compression aid
Core matrix	Hydroxypropyl cellulose	Binder and matrix-forming polymer
Core matrix	Hypromellose	Release-controlling polymer and binder
Core processing	Talc	Anti-adherent and processing aid
Film coating	Hypromellose	Film former
Film coating	Titanium dioxide	Opacifier and colorant
Film coating	Triacetin	Plasticizer
Color system	Strength-specific colorants	Product identification

The tablet is swallowed whole and must not be chewed, divided, or crushed because these actions can alter extended-release performance.[1]

How does the TOVIAZ release system work?

Fesoterodine fumarate is delivered through a hydrophilic matrix. On contact with gastrointestinal fluid, hypromellose and hydroxypropyl cellulose hydrate and form a gel layer. Drug diffusion and gradual matrix erosion control release over the dosing interval.

The formulation is commercially practical because it relies on widely available pharmaceutical excipients and standard wet-granulation or direct-compression manufacturing equipment. Its patent differentiation is more likely to arise from composition, dose strength, release profile, and manufacturing parameters than from an unusual excipient platform.

What formulation patents protect TOVIAZ?

TOVIAZ protection has historically involved patents covering fesoterodine, pharmaceutical compositions, extended-release delivery, and therapeutic use. The relevant U.S. regulatory record is the FDA Orange Book for NDA 022030, not the package label alone.[2]

Protection category	Relevance to TOVIAZ
Active pharmaceutical ingredient	Covers fesoterodine or related chemical subject matter
Salt form	Covers fesoterodine fumarate and pharmaceutical salts
Extended-release composition	Covers controlled delivery in an oral dosage form
Method of use	Covers treatment of overactive bladder and urinary symptoms
Manufacturing process	May cover preparation of the active ingredient or dosage form
Regulatory exclusivity	Separate from patent rights and dependent on FDA designation

A commercial diligence review should distinguish expired composition patents from any remaining formulation or use claims. An expired API patent does not eliminate risk from an unexpired extended-release or method-of-use patent.

What is the Orange Book status of TOVIAZ?

The relevant product is TOVIAZ extended-release tablets, NDA 022030. FDA Orange Book listings identify patents submitted by the NDA holder and any associated pediatric exclusivity or patent-use codes.[2] The product’s principal U.S. commercial barriers have largely shifted from basic active-ingredient exclusivity toward generic regulatory strategy, Paragraph IV certifications, labeling design, and formulation equivalence.

The precise status of each listed patent should be assessed against the current Orange Book and USPTO records because patent listings, delistings, terminal disclaimers, and litigation outcomes can change the effective risk profile.

When did TOVIAZ lose exclusivity?

TOVIAZ received FDA approval in April 2008.[1] Its five-year new chemical entity exclusivity therefore expired in 2013, subject to the statutory calculation and any applicable patent-term adjustments. Any pediatric exclusivity would have extended relevant exclusivity by six months if granted.

The product’s practical loss of exclusivity occurred through the expiration or expiry-adjusted narrowing of its U.S. patent estate, rather than through FDA exclusivity alone. Fesoterodine is a small molecule, so biosimilar rules do not apply. Competitive entry is governed by the abbreviated new drug application pathway.

Which companies are challenging TOVIAZ patents?

Generic competition is expected to come from ANDA applicants seeking approval for fesoterodine fumarate extended-release tablets. Public litigation and FDA records should be reviewed for applicant-specific Paragraph IV certifications, district-court complaints, settlements, and tentative approvals.

The commercial significance of a Paragraph IV filing depends on four factors:

1. Whether the applicant challenges the only remaining blocking patent.
2. Whether the patent carries a use code that can be carved out of the label.
3. Whether the formulation is therapeutically equivalent under FDA standards.
4. Whether a 30-month stay, settlement, or court injunction delays approval.

For a generic manufacturer, the lowest-risk pathway is a formulation that matches the reference product’s release behavior without reproducing unnecessary brand-specific excipient choices.

What generic formulation opportunities exist for TOVIAZ?

1. Low-cost matrix substitution

A generic manufacturer can evaluate alternative grades of hypromellose, hydroxypropyl cellulose, microcrystalline cellulose, and lactose while targeting the reference product’s dissolution profile. Small changes in polymer viscosity, particle size, substitution level, and granulation moisture can materially affect drug release.

The key development target is not excipient identity alone. It is equivalent release under multiple dissolution conditions, including pH-shift testing and agitation sensitivity.

2. Lactose-free TOVIAZ alternatives

The reference product contains lactose monohydrate.[1] A lactose-free version could use mannitol, dibasic calcium phosphate, starch, or additional microcrystalline cellulose. This creates a potential differentiation point for patients with lactose intolerance, excipient sensitivities, or preference for a simpler excipient declaration.

The main technical challenge is preserving tablet hardness, matrix integrity, and extended-release kinetics after changing the filler system.

3. Smaller tablets and improved swallowability

Extended-release tablets can be difficult for older adults, the principal overactive-bladder population. Opportunities include:

• Higher-density formulations that reduce tablet volume.
• Film coats with lower friction.
• Tablet shape optimization.
• Modified embossing that reduces swallowing resistance.
• Packaging and labeling that clearly reinforce the no-crushing instruction.

An orally disintegrating tablet is less attractive because rapid disintegration conflicts with the controlled-release requirement. A multiparticulate capsule or coated-pellet system could improve flexibility but would require a more complex bioequivalence and manufacturing package.

4. Color and excipient simplification

A generic product can reduce colorant complexity, replace titanium dioxide where permitted, or use a simpler film-coating system. These changes can lower supply-chain risk and support regional regulatory positioning.

The benefit is commercial rather than clinical. Excipient simplification can improve sourcing and reduce product complaints, but it does not by itself create a strong differentiation claim.

5. Dose-flexible products

TOVIAZ is available in 4 mg and 8 mg strengths.[1] A manufacturer could pursue a two-strength platform with common core technology, shared tooling, and proportional composition. A robust platform can reduce development cost and support launch across multiple markets.

Dose proportionality must be demonstrated rather than assumed. Changes in tablet size, polymer loading, or drug-to-excipient ratio can alter release performance.

What manufacturing and intellectual-property barriers affect TOVIAZ competitors?

The most important technical barrier is matching the reference product’s extended-release profile across the full dissolution window. Hydrophilic matrix systems are sensitive to:

• Polymer molecular weight and substitution grade.
• API particle size and crystallinity.
• Granule porosity.
• Compression force.
• Tablet hardness and friability.
• Coating weight gain.
• Storage humidity.
• Manufacturing-scale effects.

A manufacturing process that performs at laboratory scale may fail at commercial scale because granulation endpoint, drying profile, and compression dwell time affect matrix hydration.

Patent risk may arise from process claims even when the final formulation uses different excipients. A design-around strategy should document independent selection of polymer grade, granulation conditions, compression parameters, and coating composition.

How strong is the TOVIAZ patent estate?

TOVIAZ has a weaker commercial exclusivity profile than a recently launched specialty drug because it is an older small-molecule product with a conventional oral dosage form. The estate can still create entry friction where claims cover a specific controlled-release composition, salt, dosage regimen, or method of treatment.

Risk factor	Assessment
Biosimilar exposure	None; fesoterodine is a small molecule
Generic substitution risk	High after loss of effective blocking rights
Formulation complexity	Moderate
Manufacturing complexity	Moderate
Excipient differentiation	Limited but commercially useful
Clinical switching barrier	Low to moderate
Patent design-around potential	Generally meaningful for conventional matrix systems
Regulatory pathway	ANDA, subject to reference-product and patent requirements

The strongest competitive defenses are likely to come from regulatory timing, supply reliability, physician familiarity, and payer contracting rather than from excipient exclusivity alone.

What licensing and commercial opportunities exist around TOVIAZ excipients?

The most realistic licensing opportunities are platform-based rather than TOVIAZ-specific. Potential partners include excipient manufacturers, contract development and manufacturing organizations, and generic drug companies seeking validated extended-release matrix technology.

Excipient supplier opportunities

Suppliers can offer:

• High-viscosity hypromellose grades optimized for low-dose drugs.
• Co-processed cellulose systems for direct compression.
• Lactose-free filler-binder platforms.
• Low-moisture excipient systems for moisture-sensitive formulations.
• Ready-to-use film-coating systems.
• Dissolution-matched matrix platforms supported by scale-up data.

CDMO opportunities

A CDMO can package development services around:

• Reference-product characterization.
• Polymer screening.
• Design of experiments for matrix optimization.
• Comparative dissolution.
• Pilot-scale manufacture.
• Stability studies.
• ANDA CMC documentation.
• Commercial-scale technology transfer.

The strongest commercial proposition is a repeatable extended-release platform that can be adapted to other antimuscarinic or centrally acting small molecules, not a single-product excipient substitution.

Market opportunities beyond the United States

Regional opportunities include lactose-free products, reduced-cost generic products, and supply-stable versions for markets where branded TOVIAZ access is limited. Formulation requirements may differ across Europe, Asia-Pacific, Latin America, and the Middle East, particularly for colorants, titanium dioxide, excipient labeling, and bioequivalence expectations.

Geographic expansion should prioritize markets with:

• Established reimbursement for overactive-bladder treatment.
• Regulatory pathways accepting comparative dissolution and pharmacokinetic bioequivalence.
• Limited local supply of extended-release fesoterodine.
• Demand for once-daily therapies.
• Favorable government procurement or pharmacy substitution policies.

How does TOVIAZ compare with competing overactive-bladder drugs?

Product	Active ingredient	Release format	Main formulation opportunity
TOVIAZ	Fesoterodine fumarate	Extended-release tablet	Matrix optimization and lactose-free substitution
Detrol LA	Tolterodine tartrate	Extended-release capsule	Multiparticulate or capsule-based alternatives
Ditropan XL	Oxybutynin chloride	Extended-release tablet	Osmotic or matrix design-around strategies
Myrbetriq	Mirabegron	Extended-release tablet	More complex API and formulation differentiation
Enablex	Darifenacin hydrobromide	Extended-release tablet	Matrix and dose-strength platform
Gemtesa	Vibegron	Immediate-release tablet	Newer branded product and different excipient profile

TOVIAZ has a conventional generic-development profile. Mirabegron and vibegron may offer stronger branded differentiation, while tolterodine and oxybutynin have longer-established generic competition. Fesoterodine’s once-daily extended-release format remains commercially relevant where tolerability, dosing convenience, and formulary position support use.

What generic launch risks exist for TOVIAZ?

A generic launch can face four principal risks:

1. Failure to match the reference dissolution profile.
2. Patent litigation or delayed approval following a Paragraph IV certification.
3. Manufacturing variability after scale-up.
4. Limited net pricing because of therapeutic substitution and payer competition.

A successful entrant should prioritize a narrow, robust formulation design over unnecessary excipient novelty. Commercial value will depend on cost of goods, reliable supply, FDA therapeutic-equivalence status, and the ability to secure early formulary access.

Key Takeaways

• TOVIAZ is fesoterodine fumarate in a 4 mg or 8 mg extended-release tablet.
• Its excipient system uses lactose, microcrystalline cellulose, hydroxypropyl cellulose, hypromellose, talc, and standard film-coating components.
• The main technical challenge is reproducing controlled release, not recreating every inactive ingredient.
• Lactose-free, smaller, easier-to-swallow, and supply-stable formulations offer the clearest commercial opportunities.
• TOVIAZ has no biosimilar risk; competition proceeds through the generic ANDA pathway.
• Patent exposure should be assessed through current FDA Orange Book listings, USPTO records, and litigation filings.
• Excipient licensing is more attractive as a reusable extended-release platform than as a TOVIAZ-only transaction.

FAQs

Can TOVIAZ tablets be crushed or split?

No. TOVIAZ extended-release tablets should be swallowed whole. Crushing, chewing, or splitting can change drug-release behavior.[1]

Is a lactose-free generic version of TOVIAZ commercially viable?

Yes. Lactose can be replaced with alternative fillers, but the manufacturer must preserve tablet mechanical properties, dissolution behavior, stability, and bioequivalence.

Does TOVIAZ require a biosimilar development program?

No. Fesoterodine fumarate is a chemically synthesized small molecule. A competitor would generally pursue an ANDA rather than a biosimilar application.

Which excipient is most important for TOVIAZ release control?

Hypromellose is a principal release-controlling polymer, with hydroxypropyl cellulose also contributing to matrix formation and binding. Polymer grade and loading are more important than nominal excipient identity alone.

Is an orally disintegrating TOVIAZ formulation a practical opportunity?

It is technically difficult because rapid tablet disintegration conflicts with the product’s extended-release requirement. A multiparticulate or coated-pellet system is more plausible but would involve greater development and regulatory complexity.

References

1. U.S. Food and Drug Administration. (2008). TOVIAZ (fesoterodine fumarate) extended-release tablets prescribing information. NDA 022030.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2014). Guidance for industry: ANDAs for certain highly soluble immediate-release drugs submitted under the Hatch-Waxman amendments.
4. U.S. Food and Drug Administration. (2022). Guidance for industry: Extended release solid oral dosage forms: Development, evaluation, and application of in vitro/in vivo correlations.